Publications by authors named "Alessandro Corso"

Claim this Profile
T
Targeting CD38 to reduce anti-HLA antibody levels: A new and effective option to be integrated into desensitization protocols?
Viola Chiavetta, Martina Soldarini, Anna Maria Cafro, Paola Bertazzoni, Giuliana Lando, Alessandro Corso

Transpl Immunol· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Supporting treatment decision-making for patients with multiple myeloma post-DRd in Italy: a multi-criteria decision framework.
Mario Boccadoro, Angelo Belotti, Felice Bombaci, Sara Bringhen, Gabriele Buda, Alessandro Corso

BMC Cancer· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
An Update of the Appropriate Sequencing for Salvage Therapies in Multiple Myeloma.
Gregorio Barilà, Francesca Rezzonico, Laura Pavan, Alessandro Corso, Renato Zambello

Mediterr J Hematol Infect Dis· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
High-Sensitivity Flow Cytometric Detection of a Small Circulating Population of Nodal T-Follicular Helper Cell Lymphoma Angioimmunoblastic Type Cells.
Arianna Gatti, Silvia Franceschetti, Valentina Speziale, Viviana Beatrice Valli, Michela Draisci, Alessandro Corso

J Med Cases· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and Prognostic Indicators of Isatuximab, Pomalidomide, and Dexamethasone (IsaPd) in Daratumumab-Refractory Multiple Myeloma Patients: A Multicenter Real-World Study.
Enrica Antonia Martino, Daniele Derudas, Elena Rossi, Paola Stefanoni, Silvia Mangiacavalli, Alessandro Corso

Hematol Oncol· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Experts' consensus on the definition and management of high risk multiple myeloma.
Chiara Marcon, Valentina Simeon, Paola Deias, Gabriele Facchin, Alessandro Corso

Front Oncol· January 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Secondary infections worsen the outcome of COVID-19 in patients with hematological malignancies: A report from the ITA-HEMA-COV.
Patrizia Zappasodi, Chiara Cattaneo, Virginia Valeria Ferretti, Roberto Mina, Andrés José María Ferreri, Alessandro Corso

Hematol Oncol· December 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Management of infectious risk of daratumumab therapy in multiple myeloma: A consensus-based position paper from an ad hoc Italian expert panel.
Corrado Girmenia, Michele Cavo, Alessandro Corso, Francesco Di Raimondo, Pellegrino Musto

Crit Rev Oncol Hematol· April 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pomalidomide, bortezomib, and dexamethasone at first relapse in lenalidomide-pretreated myeloma: A subanalysis of OPTIMISMM by clinical characteristics.
Paul G Richardson, Fredrik Schjesvold, Katja Weisel, Philippe Moreau, Larry D Anderson, Alessandro Corso

Eur J Haematol· January 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A prognostic model for patients with lymphoma and COVID-19: a multicentre cohort study.
Carlo Visco, Luigi Marcheselli, Roberto Mina, Marianna Sassone, Anna Guidetti, Alessandro Corso

Blood Adv· January 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pomalidomide, bortezomib, and dexamethasone for multiple myeloma previously treated with lenalidomide (OPTIMISMM): outcomes by prior treatment at first relapse.
Meletios Dimopoulos, Katja Weisel, Philippe Moreau, Larry D Anderson, Darrell White, Alessandro Corso

Leukemia· June 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Daratumumab Monotherapy for Relapsed or Refractory Multiple Myeloma: Results of an Early Access Treatment Protocol in Europe and Russia.
Gordon Cook, Alessandro Corso, Matthew Streetly, Larisa P Mendeleeva, Vadim V Ptushkin

Oncol Ther· June 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical characteristics and risk factors associated with COVID-19 severity in patients with haematological malignancies in Italy: a retrospective, multicentre, cohort study.
Francesco Passamonti, Chiara Cattaneo, Luca Arcaini, Riccardo Bruna, Michele Cavo, Alessandro Corso

Lancet Haematol· October 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The association between insight and depressive symptoms in schizophrenia: Undirected and Bayesian network analyses.
Mario Amore, Martino Belvederi Murri, Pietro Calcagno, Paola Rocca, Alessandro Rossi, Alessandro Corso

Eur Psychiatry· May 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Bortezomib, cyclophosphamide, dexamethasone versus lenalidomide, cyclophosphamide, dexamethasone in multiple myeloma patients at first relapse.
Vittorio Montefusco, Alessandro Corso, Monica Galli, Ilaria Ardoino, Sara Pezzatti

Br J Haematol· March 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Smoldering multiple myeloma: the role of different scoring systems in identifying high-risk patients in real-life practice.
Federica Cocito, Silvia Mangiacavalli, Virginia Valeria Ferretti, Claudio Salvatore Cartia, Maya Ganzetti, Alessandro Corso

Leuk Lymphoma· December 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Management of infectious complications in multiple myeloma patients: Expert panel consensus-based recommendations.
Corrado Girmenia, Michele Cavo, Massimo Offidani, Francesco Scaglione, Alessandro Corso

Blood Rev· March 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Is re-challenge still an option as salvage therapy in multiple myeloma? The case of REal-life BOrtezomib re-Use as secoND treatment for relapsed patients exposed frontline to bortezomib-based therapies (the REBOUND Study).
Pellegrino Musto, Vittorio Simeon, Nicola Cascavilla, Antonietta Falcone, Maria Teresa Petrucci, Alessandro Corso

Ann Hematol· February 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Multiple Myeloma Treatment in Real-world Clinical Practice: Results of a Prospective, Multinational, Noninterventional Study.
Mohamad Mohty, Evangelos Terpos, Maria-Victoria Mateos, Michele Cavo, Sandra Lejniece, Alessandro Corso

Clin Lymphoma Myeloma Leuk· October 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The advantages of switch to subcutaneous bortezomib in the real life.
Silvia Mangiacavalli, Federica Cocito, Virginia Valeria Ferretti, Maya Ganzetti, Claudio Salvatore Cartia, Alessandro Corso

Leuk Lymphoma· June 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-term control of extensive refractory chronic graft versus host disease in a multiple myeloma relapsing after allogeneic transplant. A case report.
Federica Cocito, Silvia Mangiacavalli, Paolo Bernasconi, Anna A Colombo, Daniela Caldera, Alessandro Corso

Leuk Lymphoma· November 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Non-Secretory Myeloma: Ready for a new Definition?
Alessandro Corso, Silvia Mangiacavalli

Mediterr J Hematol Infect Dis· August 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The amyloidogenic light chain is a stressor that sensitizes plasma cells to proteasome inhibitor toxicity.
Laura Oliva, Ugo Orfanelli, Massimo Resnati, Andrea Raimondi, Andrea Orsi, Alessandro Corso

Blood· April 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Bendamustine, Low-dose dexamethasone, and lenalidomide (BdL) for the treatment of patients with relapsed/refractory multiple myeloma confirms very promising results in a phase I/II study.
Samantha Pozzi, Massimo Gentile, Stefano Sacchi, Raffaella Marcheselli, Alessandro Corso

Leuk Lymphoma· March 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Central nervous system involvement by multiple myeloma: A multi-institutional retrospective study of 172 patients in daily clinical practice.
Artur Jurczyszyn, Norbert Grzasko, Alessandro Gozzetti, Jacek Czepiel, Alfonso Cerase, Alessandro Corso

Am J Hematol· June 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis